Latest news and press releases about NeurAxis, Inc. (NRXS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics.
Price
| Price | $6.94 |
| Market Cap | $87M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 12.38 |
| EV / EBITDA | -8.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -173.28% |
| Return on Invested Capital | -109.52% |
| Return on Assets | -78.73% |
| Gross Margin | 85.56% |
| Operating Margin | -144.51% |
| Net Margin | -148.04% |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRSN · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRXS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks